DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3204-447-454$20.00
DMD 32:447-454, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lalovic, B.
Right arrow Articles by Shen, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lalovic, B.
Right arrow Articles by Shen, D. D.

QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES

Bojan Lalovic, Brian Phillips, Linda L. Risler, William Howald, and Danny D. Shen

Departments of Pharmaceutics (B.L., D.D.S.), Medicinal Chemistry (W.H.), and Pharmacy (D.D.S.), University of Washington; and Clinical Research Division, Fred Hutchinson Cancer Research Center (B.L., B.P., L.L.R., D.D.S.), Seattle, Washington

Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean Km of 600 ± 119 µM and a Vmax that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean Km of 130 ± 33 µM and a Vmax that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 µl/min/mg versus 1.5 µl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.


Address correspondence to: Dr. Danny D. Shen, Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98105. E-mail: ds{at}u.washington.edu




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
K. K. Lemberg, A. O. Siiskonen, V. K. Kontinen, J. T. Yli-Kauhaluoma, and E. A. Kalso
Pharmacological Characterization of Noroxymorphone as a New Opioid for Spinal Analgesia
Anesth. Analg., February 1, 2008; 106(2): 463 - 470.
[Abstract] [Full Text] [PDF]


Home page
J Am Board Fam MedHome page
R. Sinatra
Opioid Analgesics in Primary Care: Challenges and New Advances in the Management of Noncancer Pain
J Am Board Fam Med, March 1, 2006; 19(2): 165 - 177.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch
METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES
Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.